Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

NCT00835120 is registered in ClinicalTrials.gov with University Hospitals Cleveland Medical Center as lead sponsor.

NCT NCT00835120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00835120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
Lead sponsor
University Hospitals Cleveland Medical Center
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2009
Completion date
April 30, 2013
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression, insulin resistance, metabolic syndrome